Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.
The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.
The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.
Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.
The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
The report focuses on four primary types of asset available for purchase:
- Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations
- Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit
- Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
- Technology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 950 asset purchase deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of Asset Purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in Asset Purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of Asset Purchase deals. The chapter includes numerous case studies to enable understanding of both pure Asset Purchase deals and multicomponent deals where Asset Purchase forms a part.
Chapter 4 provides a review of the leading Asset Purchase deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active Asset Purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Asset Purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Asset Purchase deal.
The appendices to the report includes a comprehensive listing of all Asset Purchase deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends and activities in Asset Purchase dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about Asset Purchase alliances.
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 provides the reader with the following key benefits:
- In-depth understanding of asset purchase deal trends since 2014
- Analysis of the structure of asset purchase agreements with numerous real life case studies
- Comprehensive access to over 950 actual asset purchase deals entered into by the world’s biopharma companies
- Detailed access to actual asset purchase deals entered into by leading biopharma companies
- Insight into the terms included in a asset purchase agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 includes:
- Trends in asset purchase dealmaking in the biopharma industry since 2014
- Analysis of asset purchase deal structure
- Case studies of real-life asset purchase deals
- Access to over 950 asset purchase deal records
- The leading asset purchase deals by value since 2014
- Most active asset purchase dealmakers since 2014
- The leading asset purchase partnering resources
In Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
The Global Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive access to available records for over 950 asset purchase deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 provides the reader with the following key benefits:
- In-depth understanding of asset purchase partnering deal trends since 2014
- Insight into the terms included in an asset purchase agreement, together with real world clause examples
- Identify leading asset purchase deals by value since 2014
- Identify the most active asset purchase dealmakers since 2014
- Full listing of asset purchase deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
- Comprehensive access to over 950 asset purchase deals entered into by the world’s biopharma companies, together with contract documents if available
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Chapter 1 – Introduction
Chapter 2 – Trends in Asset Purchase dealmaking
2.2. Types of assets purchased
2.3. Trends in Asset Purchase deals since 2014
2.3.1. Asset Purchase dealmaking by year since 2014
2.3.2. Asset Purchase dealmaking by phase of development since 2014
2.3.3. Asset Purchase dealmaking by industry sector since 2014
2.3.4. Asset Purchase dealmaking by therapy area since 2014
2.3.5. Asset Purchase dealmaking by technology type since 2014
2.3.6. Asset Purchase dealmaking by most active company since 2014
2.4. Reasons for entering into asset purchase partnering deals
2.4.1. Business assets
2.4.2. Product assets
2.4.3. Royalty assets
2.4.4. Technology assets
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.3. The future of royalty asset purchase deals
2.6. The role of IP auction houses in asset purchase deals
2.6.1. Leading IP auction companies
2.7. The future of asset purchase agreements
Chapter 3 – Overview of Asset Purchase deal structure
3.2. Asset purchase agreement structure
3.3. Example asset purchase agreements
3.3.1. Case study 1: Product asset: QLT – Valeant Pharmaceuticals
3.3.2. Case study 2: Business asset: Merck and Co – Bayer
3.4. Anatomy of a royalty asset purchase agreement
3.5. Example royalty asset purchase agreements
3.5.1. Case study 3: Royalty asset: BioTime Acquisition Corporation– Geron Corporation
Chapter 4 – Leading Asset Purchase deals
4.2. Top Asset Purchase deals by value
Chapter 5 – Top 25 most active Asset Purchase dealmakers
5.2. Top 25 most active Asset Purchase dealmakers
Chapter 6 – Asset Purchase deals including contracts directory
6.2. Asset Purchase deals with contracts since 2014
Appendix 1 – Asset Purchase dealmaking by companies A-Z
Appendix 2 – Asset Purchase dealmaking by industry sector
Appendix 3 – Asset Purchase dealmaking by stage of development
Appendix 4 – Asset Purchase dealmaking by therapy area
Appendix 5 – Asset Purchase dealmaking by technology type
About Wildwood Ventures
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of assets purchased
Figure 2: Trends in Asset Purchase deal announcements since 2014
Figure 3: Asset Purchase deals signed at each phase of development since 2014
Figure 4: Asset Purchase deals by industry sector since 2014
Figure 5: Asset Purchase deals by therapy area since 2014
Figure 6: Asset Purchase deals by technology type since 2014
Figure 7: Top 25 most active Asset Purchase dealmakers since 2014
Figure 8: Leading royalty asset investors
Figure 9: Leading IP auction companies
Figure 10: Components of the asset purchase deal structure
Figure 11: Components of the royalty asset purchase deal structure
Figure 12: Top Asset Purchase deals by value since 2014
Figure 13: Most active Asset Purchase dealmakers since 2014
- $3,495: single-user
- $5,245: multi-user
- $10,495: single site license
- $17,495: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3M, 3M Critical & Chronic Care Solutions, 3SBio, 7D Surgical, 22nd Century, A&E Medical, Aastrom Biosciences, Abaxis, Abbott Laboratories, Abbvie, Abcam, ABEC, Abiomed, Abvitro, Acacia, Academy Medical, Acare Medical Science, Accord, Accuray, Acelity, Aceto Corporation, Achaogen, Acino Pharma, Aclaris Therapeutics, Acrotech Biopharma, Actavis (acquired by Watson), Actavis Foshan, ACT Biotech, ACT Genomics, AdaptHealth, Adello Biologics, ADMA Biologics, Admedus, Adstec, Advanced Accelerator Applications, Advanced Biologics, Advanced BioMatrix, Advanced BioScience Laboratories, Advanomics, AdvanSource Biomaterials, Advent International, Advicenne, Aegerion Pharmaceutical, Aeras, Aerial BioPharma, Aerie Pharmaceuticals, Aerogen, Aesculap, Affinium Pharmaceuticals, AGC Asahi Glass, Agena Bioscience, Agenus Bio, Agilent Technologies, Agrium, AiPing Pharmaceutical, AIT Therapeutics, Akashi Therapeutics, Akkadeas Pharma, Akorn, Akoya Biosciences, Akrimax Pharmaceutical, Albany Molecular Research, Albemarle, Albumedix, Alchemia, Alere, Alexza Pharmaceuticals, Alfasigma, Alfred E. Mann Institute for Biomedical Engineering, AliveGen, ALK-Abello, Alkame, Alkermes, Allegheny General Hospital, Allegis Holdings, Allergan, Allergan (name changed from Actavis), Alliance Pharma, Almac Group, Almirall, Alphagen Laboratories, Alphatec Spine, Alpine Immune Sciences, ALS Biopharma, Altavant Sciences, Altermune Technologies, Alvine Pharmaceuticals, Alvogen, AM-Pharma, Amarantus BioSciences, Amcor, Amendia, Amerigen Pharmaceuticals, AmerisourceBergen, AMFIL Technologies, Amgen, Amherst Pharmaceuticals, Amilabo, Amneal Pharmaceuticals, AMN Healthcare, Amphastar Pharmaceuticals, AmpliPhi Biosciences, Ampronix, AMP Therapeutics, Amring Pharmaceuticals, Amygdala Neurosciences, Anapure BioScientific, Andromeda Biotech, Angelini Pharma, Angiodynamics, ANI Pharmaceuticals, AnnaMed, Antares Pharma, Antech, Anthera Pharmaceuticals, AOAExcel, Apexigen, Apollo Endosurgery, ApoPharma, Apotex, Applied Biology, Applied Medical, Applied StemCell, Aptalis Pharmaceutical Technologies, Aptevo Therapeutics, APT Therapeutics, Aptuit, Aqua Pharmaceuticals, Aradigm, Aralez Pharmaceuticals, Argon Medical Devices, Ario Pharma, Arjo, Armetheon, Array Biopharma, Arrevus, Arrowhead Pharmaceuticals, Arrow Pharmaceuticals, Arseus, Arteriocyte Medical Systems, Arthrosurface, Artizan Biosciences, ARxIUM, Arysta LifeScience, Asana Biosciences, Aseptix, AS Kevelt, Asklepion Pharmaceuticals, Asklepios Biopharmaceutical, Aspen Global, Aspen Holding, Aspen Surgical Products, Assertio Therapeutics, Astellas Pharma, Astellas Pharma US, Asterand Bioscience, Astero Bio, Astion Pharma, AstraZeneca, Asuragen, Atlab Pharma, ATL Technology, Atnahs Pharma, Atossa Genetics, Audax Private Equity, Auris Medical, Aurobindo Pharma, Aurora Cannabis, Aurora Diagnostics, Autotelic, Avadel Pharmaceuticals, AvanSci Bio, Avara Pharmaceutical Services, Avid Bioservices, Aviir Diagnostics, Avista Pharma Solutions, Avita Medical, Axis Biotec Group, Aytu BioScience, Azaya Therapeutics, Back Bay Scientific, Banco de Sangre de Servicios Mutuos, BarioSurg, BASF, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Animal Health, Bayer Healthcare, Bayer Innovation, Bayer Technology Services, BBI Solutions, Beckman Coulter, Becton Dickinson, Bedford Laboratories, Beiersdorf, BeiGene, Beijing Genomics Institute (BGI), Bellus Health, Ben Venue Laboratories, Berkeley Lights, BGI, Bial, Bioanalytical Laboratory Services, BioAnalytical Systems, BioCad Holding, BioCorRx, Biodelta Nutraceuticals, Biodesix, Bioengineering Laboratories, Biogen, Biohaven Pharmaceutical Holding, BioLegend, Biolin Scientific, BioMarin Pharmaceutical, BioMedical Drug Development, BioMedical Research, Biomerics, BioMotiv, Bionik Laboratories, BioNTech, Biophage Pharma, BioPharma Services, Bioprocess Capital Ventures, Biopsy Sciences, Biosign Technologies, Biostar, Biostem US, BioSurface Engineering Technologies, Biota Pharmaceuticals, BioTelemetry, Biotest Pharmaceuticals, Bioventus, BMG Pharmaceuticals, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bora Pharmaceuticals, Boston Scientific, Boston Topicals, Bovie Medical, Braeburn Pharmaceuticals, Brainsway, Breckenbridge Pharmaceutical, Bristol-Myers Squibb, BroadOak Capital Partners, Bruker, BUCHI Labortechnik, Burgerhospital, BWK, BWX Technologies, C3J Therapeutics, C4X Discovery, California Institute for Biomedical Research, Camino Partnership, Candela, Candel Therapeutics, Canon, Canon BioMedical, Cantel Medical, Capital One, Capnia, Capricor Therapeutics, Caprion Proteomics, CaptoGlove, Cardinal Health, CardioCORE Lab, Cardiome Pharma, CardioSert, Cardiovascular Systems, Caret Pharma, CASI Pharmaceuticals, CAS Medical Systems, Casper Pharma, Catalent, Catalyst Biosciences, Catheter Research, CBL Group, Cegedim, Celdara Medical, Celexion, Celgene, Celgene Cellular Therapeutics, Cellana, Cellectis, Celling Biosciences, Cell MedX, Cellmic, Cellular Biomedicine, Celonic, CeloNova BioSciences, Celsee, Celyad, CEM, CEN Biotech, Centauri Therapeutics, Centinel Spine, Centogene, Centrexion, Centron Diagnostics, Centurion Medical Products, Century Medical, Cepheid, Cequr, Cerecor, Cerner, Cerus, Cervel Neurotech, Chembio Diagnostics, Cheplapharm Arzneimittel, Cherwell Laboratories, CHG Hospital Beds, Chiesi Farmaceutici, China Biologic Products, China Medical System, Chip-Man Technologies, ChoiceSpine, Chroma Therapeutics, Chronos Therapeutics, Cilag AG, Cipher Pharmaceuticals, Cipla, Cirrus Pharmaceuticals, CJ CheilJedang, Clayton Dubilier & Rice, Cleveland BioLabs, Cleveland Clinic, Cleveland HeartLab, Clinical Innovations, Clinical Laboratory Partners, Clinigen, Clinique Les Trois Soleils, Clinquest, Co-Diagnostics, Coating Place, Cobalt Healthcare Consultants, Codexis, Coeptis Pharmaceuticals, Collegium Pharmaceuticals, Colorcon, CombinatoRx, Concert Pharmaceuticals, Concord Biosciences, Concordia Healthcare, Concordia Pharmaceuticals, Concord Medical Services Holdings, ContextVision, Conventus Orthopaedics, Convoy Therapeutics, Cooper-Vemedia, Cooper Companies, Coqui RadioPharmaceuticals, Cord Blood Registry, Cordis, CorDynamics, Corin, CorMatrix Cardiovascular, Corning, Cortice Biosciences, Cosmed Group, Covance, Covetrus, Covidien, Covis Pharmaceutical, Cranford Pharmaceuticals, C R Bard, CR Kennedy & Company, CROS NT, Crown Bioscience, Crown Laboratories, Crucell, Cryolife, CSL, CSPC Pharmaceutical Group, CTD Holdings, CTI BioPharma, CTX Technology, Cumberland Pharmaceuticals, CURE Pharmaceutical, Custopharm, CVC Capital Partners, Cyanotech, Cypralis, Cytonet, Cytori Therapeutics, Cyxone, Dainippon Sumitomo Pharma, Danaher, Daniel Alain Life Science, Dartmouth College, DAS Therapeutics, Daylight Medical, Debiopharm, Debiotech, DeciBio Consulting, Delta, Dendreon, Denovo Biopharma, Department of Veterans Affairs, DepoMed, DePuy, DermaPort, Devicor Medical Products, DiagnoCure, Diagnoplex, Diamedix, DiaSorin, dievini Hopp BioTech, Digirad, Diosynth, Distal Access, Diversey Care, DJO Global, Dominion Diagnostics, Dong-A Pharmaceutical, DOSE Medical, DPT Laboratories, Dr. Reddy's Laboratories, Dr. Susan Love Research Foundation, DS Healthcare, DSM Nutritional Products, DT MedTech, Ducere Pharma, DuPont, DuPont Industrial Biosciences, Duran Group, Durect, Dyadic International, Easton Pharmaceuticals, Eckert & Ziegler, Ecolab, Ecole Polytechnique de Montreal, Edan Diagnostics, Eddingpharm, Edge Biosystems, EdiGene, Edogawa Hospital, Edwards Lifesciences, Egalet, Ehave, Eiger BioPharmaceuticals, Eisai, Ekso Bonics, Elanco, Elanix Biotechnologies, Elekta, Elencee, Eleven Biotherapeutics, Eli Lilly, ELT Sight, Ember Therapeutics, Embolitech, EmbryoTrans Biotech, EMD Millipore, Emergent BioSolutions, Emmes, Enaltus, EnBiotix, Encore Medical, Endo International, Endonovo Therapeutics, Endo Pharmaceuticals, EnteroMedics, Envigo, Envisia Therapeutics, EnWave, Enzymatics, Enzyvant Science, EpiBiome, EPI Health, EQT, Equipois, ERBA Diagnostics, ERT, Espada Dermatology, Ethicon Endo-Surgery, Ethismos Research, EUSA Pharma, Euthymics Bioscience, Event Cardio Group, Evolva, Evonik Industries, Evotec, Exactech, Expedeon, Exponent Private Equity, Eyevance, F-Star Alpha, Famy Care, Faulk Pharmaceuticals, Ferring Pharmaceuticals, Firsthand Technology, Flamel Technologies, Flamma, Flexion Therapeutics, Flexpoint Sensor Systems, FMC, Focus Laboratories, Forest Pharmaceuticals, Formex, Fortis Healthcare, Fortive, Fosun Pharmaceutical, Fougera Pharmaceuticals, Foundation Consumer Healthcare, Frankfurt University Hospital, Freedom Meditech, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, Frontier Scientific Services, Fruh Control, FSC Laboratories, Fujifilm, Fujifilm Diosynth Biotechnologies, Fulcrum, G&W Laboratories, Galderma, Galecto Biotech, Galen, Galena Biopharma, Gallazzi, Galmed Pharmaceuticals, Gamma Medica, Gardia Medical, GE Healthcare, Gem Pharma, Gen-Probe, GeneNews, GenePOC, GeneQuine Biotherapeutics, Genesee BioMedical, Genesis Biotechnology Group, Genetrix, GeneWorks, Genmab, Genzyme, George Clinical, Gerresheimer, Gestion Univalor, Gesynta Pharma, Gilead Sciences, Ginkgo BioWorks, Ginolis, Glaukos, GlaxoSmithKline, Glenveigh Medical, Global Life Safety Group, Global Medical Solutions, Globus Medical, Glycotope Biotechnology, Godrej, GO Scale Capital, Gowan Crop Protection, GrandOmics Biosciences, Great Belief International, Grifols, Grunenthal, GT Biopharma, Guangdong Lewwin Pharmaceutical Research Institute, Guerbet, Guiyang Dalin Biotechnology, Guizhou Taibang Biological Products, H2-Pharma, Hackensack University Medical Center, Halo Labs, Halyard Health, Hancock Jaffe Laboratories, Harvard University, Healeon Medical, Health Diagnostics Laboratory, HeavenlyRx, Helix Medical, HemaCare, Henry Ford Health System, Henry Schein, Heritage Group, Heritage Pharmaceuticals, Heska, Hi-Tech Pharmacal, High Ridge Brands, Hikma Pharmaceuticals, Hill-Rom, Hillstream BioPharma, HLD, Hoffmann La Roche, Holmdel Pharmaceuticals, Hologic, Honeywell, Horizon CombinatoRx, Horizon Discovery, Horizon Pharma plc, HOYA Vision Care, Hudson-Alpha Institute for Biotechnology, Humanetics, Human Longevity, Huntsman, Hy BioPharma, i2 Pharmaceuticals, iAnthus Capital, IBA Molecular Imaging, iCAD, Icagen, iCardiac Technologies, ICU Medical, iDD Biotech, IDT Biologika, IEH Laboratories & Consulting Group, IFM Therapeutics, Igenica, Ignyta, Illumina, Imaflex, Immuneed, ImmuneHealth, Immune Targeting Systems, Immune Therapeutics, ImmunGene, ImmunoCellular Therapeutics, ImmunogenX, ImmunoTek Bio Centers, Impax Laboratories, Implant Sciences, Imprimis Pharmaceuticals, IMS Health, Incuron, Indivior, InfusAID, InfuSystem Holdings, Initiator Pharma, Innate Pharma, Innospec, INNOVAMEDICA, Innovate Biopharmaceuticals, Innovation Skane, Innovative Diagnostic Laboratory, Innovus Pharmaceuticals, iNova Pharmaceuticals, Inovio Pharmaceuticals, Insightra Medical, Instem, Intas Biopharmaceuticals, Intavis Bioanalytical Instruments, Integra LifeSciences, Integrated DNA Technologies, Integrative Medicine, Intelligent Hospital Systems (IH Systems), International Vitamin, Interpace Diagnostics, Interpace Diagnostics Group, Interventional Spine, IntraFuse, Intrexon, Intuitive Surgical, Invacare, Invekra, Ipsen, iQ Group, Irras, IRX Therapeutics, Isarna Therapeutics, iSense CGM, ISIS Innovation, Isologic Innovative Radiopharmaceuticals, Isto Technology, Itamar Medical, Iuvo BioScience, Iveria Technologies, IVF Bioscience, J. Morita, Janssen Biotech, Janssen Diagnostics, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Sciences, Japan Tobacco, Jazz Pharmaceuticals, Johnson & Johnson, JOT Automation, Juvise Pharmaceuticals, Kalon Biotherapeutics, Kane Biotech, karmadata, Karo Pharma, Kashiv BioSciences, KBI BioPharma, KCR, KD Pharma, KEDPlasma, Kemwell BioPharma, Kennedy Health System, Kessler Foundation, Keyrus Biopharma, Kimberly-Clark, Kindstar Globalgene Technology, KineMed, Kinetic Concepts, King's College Hospital, Kiniksa Pharmaceuticals, Knight Therapeutics, KNOW Bio, Kolltan Pharmaceuticals, Kramer Laboratories, Kyocera, L'Oreal, L-3 Communications, Laboratory Corporation of America, Laboratory Supply Company (LABSCO), Labworks, Lake Consumer Products, Lantheus Holding, Lanthio Pharmaceutical, Lanxess, Laurel Venture Capital, Lautus Pharmaceuticals, LeMaitre Vascular, LensAR, Lentigen, LEO Pharma, Les Laboratoires Servier, LFB Biotechnologies, LGC, LifeArc, LifeCell, Lifecode, Lifecycle Biotechnologies, LifeHealth, LifeLabs Medical Laboratory Services, Ligand Pharmaceuticals, Lima Corporate, Lincoln Equities Group, Lineage Cell Therapeutics, LineaRx, LivaNova, Locemia Solutions, Locus Biosciences, Lonza, Los Angeles Biomedical Research Institute, Lotus Biotechnology Development, Lotus Pharmaceuticals, Louisiana State University, LSNE Contract Manufacturing, LTS Lohmann Therapie-Systeme, Luitpold Pharmaceuticals, Lumara Health, LumenR, Luminex, Lumora, Luna Innovations, Lupin, Luye Pharma Group, MAB Discovery, MabVax Therapeutics, Macrogen, Macrogenics, Madison Dearborn Partners, Malin, Mallinckrodt Pharmaceuticals, Malvern Instruments, Mannin Research, Mapi, Marathon Pharmaceuticals, Mariel Therapeutics, Marina Biotech, Marin Community Foundation, Marinomed Biotechnologie, Marizyme, Masimo, Matawan Pharmaceuticals, Matrivax, Mayne Pharma, Mayo Clinic, MC3 Cardiopulmonary, McKesson, MD Anderson Cancer Center, MDRM Group (Canada), Meda Pharmaceuticals, MEDCIS Pathlabs, Medela, Medeon Biodesign, MedGenome, Medical Developments International, Medicall Biomedikal, Medical Products Laboratories, Medical University of Vienna, Medicated Markets International, MediGene, Medigus, Medimass, Medimetrics, MediPines, Medivation, Medivir, Medline Industries, MedPlast, MedQualis, Medtronic, Melanovus Oncology, MELA Sciences, Melinta Therapeutics, MemorialCare Health System, Menarini, Mentice, Mercachem, Merck and Co, Merck Animal Health, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merial, Meridian Bioscience, Merit Medical Systems, Merqurio, Merrimack Pharmaceuticals, Merus Labs International, Merz, METabolic EXplorer, Metabolix, Metasurg, Metrion Biosciences, Michael Bubolz, Microbot Medical, Micro Hydraulics, Microlin Bio, MicroPort Scientific, Microsoft, MilliporeSigma, Miltenyi Biotec, Mind Medicine, Minebea, Misonix, Mitralign, Mitsubishi Chemical, Mitsui Chemicals, MJ Biologics, MLase, Moberg Pharma, Modern Mobility Aids, Molecular Response, MolecuLight, Moleculin Biotech, Molnlycke Health Care, Molplex Pharmaceuticals, Molteni Farmaceutici, Monopar Therapeutics, Montagu Private Equity, MorphoSys, Mount Sinai Health System, MSC, Mylan Laboratories, Mylan Pharmaceuticals, Myovant Sciences, Nanion, NanoProteagen, Nanotherapeutics, NanoViricides, NantHealth, NantPharma, Natera, National Cancer Center, National Research Council Canada, Neogen, Neograft Technologies, Neos Therapeutics, NeoSync, Neovasc, Neptune Wellness Solutions, Nestle, Nestle Health Science, NetScientific, NeuroBo Pharmaceuticals, NeuroOne, NeuroSearch, NeuTec Pharma, Neutronix Quintel, Nexeon MedSystems, Nextmune, Nexus Pharmaceuticals, Nicklaus Children’s Hospital, Nicox, Nikkiso, Nordion, Norgine, North American Science Associates, Northwestern Memorial Hospital, Nostrum Pharmaceuticals, NovaDel Pharma, NovaDigm Therapeutics, Novalere, Novan Therapeutics, Novartis, Novartis Consumer Health, Novarum, Novasep, Noven Pharmaceuticals, Novigenix, NovImmune, Novogene, Novolytics, Novo Nordisk, NOW Diagnostics, nSpire Health, Nuvisan group, Nuvo Pharmaceuticals, Nuvo Research, OBI Pharma, Occlugel, Oculus Innovative Sciences, Ohr Pharmaceuticals, OJSC Pharmsynthez, Olink Bioscience, Olon, Olympus Biotech, Omnia Biologics, OmniBiome Therapeutics, OmniComm Systems, Oncimmune, Oncimmune Ltd, Oncodesign, Oncologie, OncoQuest, OncoVision, Optum Life Sciences, Oragenics, Orchard Therapeutics, Orexigen Therapeutics, Orexo, Organogenesis, Orphan Canada, Orphic Therapeutics, Orthofix, Ortho Regenerative Technologies, Osteomed, Otifex Therapeutics, Ottawa Hospital Research Institute, Oxford Instruments, OxyPharma, P2P Staffing, Pace Wellness, Pacific Biosciences, Panasonic Healthcare, Panther Biotechnology, Paragon Medical, Par Pharmaceutical, Partner Therapeutics, Patient Genesis, Patterson Companies, Paulaur Corporation, PaxVax, PEAR Therapeutics, PediaVision, PeriGen, Periphagen Holdings, PerkinElmer, Perkins Healthcare Technologies, Pernix Therapeutics, Perrigo, PetIQ, PetLife Pharmaceuticals, Pevion, Pfizer, Phagelux, Pharma-Bio Serv, PharmaCell, PharmaChem, Pharmacia, Pharmacyclics, PharmaEngine, Pharmalink AB, Pharma Logistics, Pharmaron, PharmaVentures, Pharmaxis, PharmEste, Pharming Group, Pharmstandard, PhaseBio Pharmaceuticals, PHC Holdings, Phenomics Health, Phibro Animal Health, Philips, Philips Healthcare, PhotoMedex, Photonamic GmbH, Piedmont Pharmaceuticals, Pierre Fabre, Pillar Palatal, Piramal, Piramal Healthcare, Platine Pharma Services, Plethora Solutions, Plumbline Life Sciences, PMC Group, PM Clinical, PolyOne, Polypeptide Laboratory, Polypore, Poniard Pharmaceuticals, Portage Biotech, Pozen, Pragma Pharmaceuticals, Praha Vaccines, Precera Bioscience, Precisa Medical Instruments, Precision Eye Services, Premier Inc, Presbia, Prestige Brands, Prestium Pharma, Prevent Biometrics, Primex Pharmaceuticals, Primix, Probiodrug, ProBiora Health, Procter & Gamble, Pro Dex, Profound Medical, Progenity, Proliant Health and Biologicals, Promethera Biosciences, Promius Pharma, Prophase Labs, ProtoKinetix, Provention Bio, Psomagen, Publicis Healthcare Communications Group, Pulmagen Therapeutics, Pulmonox, Pulse Biosciences, Pulssar Technologies, Purdue Pharma, PureTech Health, Q BioMed, Qiagen, QT Vascular, Quantum Materials, Quest Diagnostics, Quest PharmaTech, Quintiles IMS Holdings, R-Pharm, R-Tech Ueno, RadCore Labs, RadNet, Raisio, RaNA Therapeutics, Randob Labs, Raptor Pharmaceutical, Real Brands, Realm Therapeutics, Recipharm, Recordati, Recro Pharma, Regen BioPharma, Regeneron Pharmaceuticals, Regenicin, Remedy Pharmaceuticals, Renaissance Acquisition Holdings, Renovis, Repligen, ReproCell, ReShape Lifesciences, ReShape Medical, Retrophin, RetroSense Therapeutics, Revive Pharmaceuticals, rEVO Biologics, Rex Medical, Rich Pharmaceuticals, Rio Grande Neurosciences, Rising Pharmaceuticals, Roche, Roche Diagnostics, Rodo Medical, Roivant Sciences, Ropack, RoundTable Healthcare Partners, RoverMed BioSciences, Roxall, Royal Philips Electronics, RTI Surgical, S2 Interactive, SafeWire, Saint-Gobain Performance Plastics, Salvin Dental Specialties, Sample6, Sandoz, Saniona, Sanofi, Santen Pharmaceutical, Saol Therapeutics, Sarepta Therapeutics, Sartorius, Sartorius Stedim Biotech, Savant HWP, Sawai Pharmaceuticals, Scapa Healthcare, Schering-Plough, Schoeller Technologies, Scientific Industries, Scripps Research Institute, Scynexis, Sea Lane Biotechnologies, Sealed Air, Searchlight Pharma, Sebacia, Sectra, SeD Biomedical, Seelos Therapeutics, Selenity Pharmaceuticals, Sentynl Therapeutics, Sequenom, SERB Pharmaceuticals, Seventh Wave, Shandong Boan Biological Technology, Shandong Xinhua Pharmaceutical, Shardna, Shionogi, Shire Laboratories, Shire Pharmaceuticals, Siegfried, Siemens, Siemens Healthcare, Sienna Biopharmaceuticals, Sierra Oncology, Sigma-Aldrich, Sigma-Tau, Signet Healthcare Partneers, SI Group, Simplyfeye, Sinclair IS Pharma, Sinclair Research, Singulex, SI Pharmaceuticals, Sirio Pharma, SK Biopharmaceuticals, SK Capital Partners, SKS Ocular, SkyePharma, Sloan Pharma, Small Bone Innovations, Smith & Nephew, Smithers Avanza, Smiths Medical, Snoring Center USA, Social Reality, Sofar, Sofregen Medical, Soligenix, Sorin Group, Sorrento Therapeutics, Spartan Medical, Spear Pharmaceuticals, Spectranetics, Spectrum Pharmaceuticals, SpePharm, Spinomix, Spiracur, SQI Diagnostics, STADA Arzneimittel, Stanford Health Care, Starpharma, StatSure Diagnostic Systems, Stellar Biotechnologies, Stemedica Cell Technologies, Stemedica Internaional, Stenning, Stericycle, Sterigenics, St Jude Medical, Straumann, Strides Arcolab, Stryker, SugarLeaf Labs, Sumitovant Biopharma, Sunovion Pharmaceuticals, Sun Pharmaceutical, Sunshine Biopharma, Sunstar Suisse, SunTech Medical, Super-T Cell Cancer, Surgical Specialties, SurModics, Swedish Orphan Biovitrum, Symmetry Medical, Symmetry Surgical, Symplmed Pharmaceuticals, Synaptive Medical, Synartro, SynCore Biotechnology, Synergetics, Synergy Pharmaceuticals, Synexus, SynGen, Synthetic Genomics, Synthon, Systagenix Wound Management, Tabuk Pharmaceutical, Taisho Pharmaceutical, Takara Bio, Takeda Pharmaceutical, Targacept, Tasly Pharmaceuticals, Taureon, TauTona, TAXIS Pharmaceuticals, TearLab, Tec-Pharm, Tecan, Techcomp, Tecomet, Teijin Nakashima Medical, Tekni-Plex, Teleflex, Teligent, Telix Pharmaceuticals, Temmler Group, TerSera Therapeutics, Terumo, Terumo Cardiovascular Systems, Tesaro, Tesla Digital, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, The Green Organic Dutchman Holdings, The Medicines Company, Theraclion, Theragen, Theragene Pharmaceuticals, Theragenics, Therakine, Therapeia, Therapeutic Solutions International, Therapix Bio, Therapure Biopharma, Theravance Biopharma, ThermiGen, Thermo Fisher Scientific, ThermoGenesis, THINK Surgical, Threshold Pharmaceuticals, Tibet Rhodiola Pharmaceutical Holding Co, TiGenix, Tilray, Tissue Regeneration Systems, Titan Pharmaceuticals, Tiziana Life Sciences, TKL Research, TNK Therapeutics, Tonus Therapeutics, Torrent Pharmaceuticals, Toshiba, Toxikon, TPG Capital, Transcatheter Technologies, TransEnterix, Transgene, Transgene Tasly Biopharmaceutical, Transgenic Rabbit Models, Transgenomic, Transition Therapeutics, Transpire, Trendlines Group, Trinity Compound Solutions, Trinity Medical Devices, Tripex Pharmaceuticals, Trividia Health, Trophikos, Turing Pharmaceuticals, Twist Bioscience, uBiome, UCB, UDG Healthcare, Ultimovacs, Ultra Scientific, Unichem, Unilever, United Medical Systems (UMS), United Therapeutics, University of Alberta, University of Florida, University of Guelph, University of Miami, University of Oklahoma, University of Pittsburgh Medical Center, University of South Florida, University of Texas, University of Toronto, University of Washington, Upsher-Smith, Urgo Laboratories, Urovant Sciences, USMD Holdings, Valeant Canada Limited, Valeant Pharmaceuticals, Valeo Pharma, Valneva, Vance Street Capital, Vantage Endoscopy, Varex Imaging, Varian Medical Systems, Vascular Graft Solutions, VCA Antech, Vector Oncology, Veeva Systems, Velocity Medical Solutions, Vention Medical, Venus Medtech, Verastem, Verios Agro, Verisante Technology, Vertex Pharmaceuticals, Vertical Pharmaceuticals, Vestagen, Vetoquinol, Viamet Pharmaceuticals, ViewRay, Vigene Biosciences, ViiV Healthcare, Viracta Therapeutics, Virbac, Virox Technologies, Viscogliosi Brothers, Vision Acquisition, Vistinct, Vitatex, Vitesse Biologics, ViVex Biomedical, Vivus, VM Pharma, VolitionRX, VuCOMP, Vyera Pharmaceuticals, W.R.Grace, Walter Reed Army Institute of Research, Warp Drive Bio, Wasas, Waters Corporation, Watson-Marlow Fluid Technology Group, Wavelength Pharmaceuticals, Wave Neuroscience, WCCT Global, Welch Allyn, WellSpring Pharmaceutical, Wenzel Spine, Wilex, WIRB-Copernicus Group, Wittenstein, W L Gore, Wockhardt, Woodfield Pharmaceutical, Wright Medical, Wuhan Humanwell, WuXi Biologics, WuXi PharmaTech, X2 Biosystems, XBiotech, Xellia Pharmaceuticals, Xenetic Biosciences, XRpro Sciences, Xtreme Technologies, Yantai Dongcheng Biochemicals, Yokogawa Electric, York Instruments, Young Dental, Young Innovations, Z-Medica, Zahra Holdings, Zalicus, Zentiva, Zhejiang Chiral Medicine Chemicals, Zimmer Biomet, Zoe Medical, Zoetis, Zogenix, Zoll Medical, ZYUS Life Sciences